ERShares Private-Public Crossover ETF (ENTR)
ARCA ARCA Primary NASDAQ (NMS) Summary
ENTR Chart
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. “ELEVATE-45-201 is the most advanced clinical study of a conjugated exon skipping therapy for individuals amenable to exon 45 skipping and offers the potential to address a large Duchenne subpopulation with significant unmet medical needs,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 45 skipping.
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. The global ELEVATE-44 program, which includes the ELEVATE-44-102 study in the U.S. and ELEVATE-44-201 outside of the U.S., will cover a broad population of patients with DMD and support evaluation of ENTR-601-44 in patients with both early and advanced disease.
ERShares Private-Public Crossover ETF Dividends
| ENTR 20 Dec 2023 | Other | $0.01 Per Share |
| ENTR 21 Dec 2021 Paid | Other | $8.73 Per Share |
| ENTR 21 Dec 2020 Paid | Other | $1.65 Per Share |
| ENTR 19 Dec 2019 Paid | Other | $0.01 Per Share |
| ENTR 18 Dec 2018 Paid | Other | $0.03 Per Share |
ERShares Private-Public Crossover ETF Earnings
| ENTR 20 Dec 2023 | Other | $0.01 Per Share |
| ENTR 21 Dec 2021 Paid | Other | $8.73 Per Share |
| ENTR 21 Dec 2020 Paid | Other | $1.65 Per Share |
| ENTR 19 Dec 2019 Paid | Other | $0.01 Per Share |
| ENTR 18 Dec 2018 Paid | Other | $0.03 Per Share |
ERShares Private-Public Crossover ETF (ENTR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ERShares Private-Public Crossover ETF ever had a stock split?
ERShares Private-Public Crossover ETF Profile
| ARCA Exchange | US Country |
Overview
This investment fund focuses on accumulating a portfolio of equity securities, emphasizing investments in both mid and large-cap companies. These companies are primarily traded on significant U.S. stock exchanges such as the NASDAQ and the New York Stock Exchange. By targeting these market segments, the fund seeks to leverage the growth potential and stability of established corporations while also exploiting the dynamic growth opportunities presented by mid-sized companies. It is important to note that the fund operates with a non-diversified status, meaning it may allocate a larger portion of its assets to fewer securities, potentially increasing the risk and volatility compared to diversified funds.
Products and Services
- Common Stocks:
These are shares that represent ownership in a company, giving the holder a claim on a portion of the corporation's assets and profits. Common stockholders typically enjoy voting rights, allowing them to influence corporate policy and management decisions at shareholders' meetings.
- Preferred Stocks:
Preferred stocks are shares that offer owners preferential dividend payments, often at a fixed rate, before any dividends are paid to common stockholders. However, they usually come without the voting rights that common shareholders enjoy.
- Convertible Preferred Stocks:
This type of preferred stock can be converted into a predetermined number of common shares, usually at the discretion of the shareholder. This feature provides potential for capital appreciation, in addition to the fixed-income benefits of preferred stocks.
- American Depositary Receipts (ADRs):
ADRs represent shares in a foreign company that are traded on U.S. exchanges. These financial instruments allow U.S. investors to invest in overseas companies without the complexities of dealing with foreign exchanges. The fund only deals with sponsored ADRs, where the foreign company has a formal agreement with a depositary bank in the U.S., ensuring a level of regulatory compliance and transparency.
- Global Depositary Receipts (GDRs):
Similar to ADRs, GDRs are bank-issued certificates representing shares in a foreign company, but they are primarily traded on international markets outside the U.S. Like ADRs, the fund invests exclusively in sponsored GDRs, which are subject to regulatory oversight and offer investors a degree of financial security.
Contact Information
